Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
| Title | Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Bourbouli, M., Rentzos M., Bougea A., Zouvelou V., Constantinides V. C., Zaganas I., Evdokimidis I., Kapaki E., & Paraskevas G. P. |
| Journal | Dement Geriatr Cogn Disord |
| Volume | 44 |
| Issue | 3-4 |
| Pagination | 144-152 |
| Date Published | 2017 |
| ISSN | 1421-9824 |
| Abstract | BACKGROUND: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are nowadays recognized as spectrum disorders with a molecular link, the TAR DNA-binding protein 43 (TDP-43), rendering it a surrogate biomarker for these disorders.METHODS: We measured cerebrospinal fluid (CSF) levels of TDP-43, beta-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau protein phosphorylated at threonine 181 (τP-181) in 32 patients with ALS, 51 patients with FTD, and 17 healthy controls. Double-sandwich commercial enzyme-linked immunosorbent assays were used for measurements.RESULTS: Both ALS and FTD patients presented with higher TDP-43 and τT levels compared to the control group. The combination of biomarkers in the form of the TDP-43 × τT / τP-181 formula achieved the best discrimination between ALS or FTD and controls, with sensitivities and specificities >0.8.CONCLUSION: Combined analysis of TDP-43, τT, and τP-181 in CSF may be useful for the antemortem diagnosis of ALS and FTD. |
| DOI | 10.1159/000478979 |
| Alternate Journal | Dement Geriatr Cogn Disord |
| PubMed ID | 28848086 |
